ImmunityBio (IBRX) Could Be 39% Undervalued Following Its Bladder Cancer Trial Progress

ImmunityBio (IBRX) has advanced a key bladder cancer program to its next phase by locking the database for Cohort A of its QUILT-2.005 registrational trial, which clears the way for final efficacy analysis.

ImmunityBio’s latest bladder cancer data drop lands after a huge run, with the share price delivering a 332.67% year to date return and a 264.17% total shareholder return over the past year. The recent 7 day gain of 6.33% and 90 day share price return of 21.90% come alongside a 30 day pullback of 7.42%, suggesting momentum has cooled slightly in the very short term rather than reversing the longer trend.

Capitalize on ImmunityBio's cancer immunotherapy momentum by lining up your next biotech idea from our hand-picked 36 healthcare AI stocks.

The share price now sits well below both analyst targets and some intrinsic value estimates after that sharp run. Is this simply caution about ImmunityBio’s cash burn and losses, or a mispriced bladder cancer platform story that valuation numbers can clarify next?

Most Popular Narrative: 39% Undervalued

ImmunityBio last closed at $8.74, while the most followed narrative pegs fair value closer to $14.25. This view places significant emphasis on how its bladder cancer and broader immunotherapy pipeline develop over the next few years.

The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

The broad use of checkpoint inhibitors across many tumor types has created a large pool of patients with limited options after checkpoint failure. ANKTIVA combinations targeting this setting, such as in QUILT-3.055, address an existing treatment gap that could influence future revenue and potentially support higher utilization per patient.

See why 21 investors see ImmunityBio as 39% undervalued.

Result: Fair Value of $14.25 (UNDERVALUED)

Still, the ImmunityBio story leans heavily on ANKTIVA and ambitious analyst assumptions, so any clinical setback or slower than expected uptake could quickly challenge that 39% undervalued narrative.

Find out about the key risks to this ImmunityBio narrative.

Next Steps

Sentiment around ImmunityBio is mixed, with strong optimism balanced against clear concern about risks. Consider both sides carefully for yourself and check the 3 key rewards and 1 important warning sign.

Ready for more investment ideas beyond ImmunityBio?

If ImmunityBio has sharpened your focus on opportunity and risk, do not stop here. Broader idea flow often separates reactive traders from prepared investors.

• Target potential bargains by scanning companies that combine quality fundamentals with appealing valuations through the 30 high quality undervalued stocks.
• Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (23 results) that could help you avoid fragile businesses when conditions get tougher.
• Get ahead of the crowd by searching for tomorrow's potential standouts with the 18 high quality undiscovered gems.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com